Reduced CCL2 Expression in Ovarian Adenocarcinoma
Author Information
Author(s): Arnold J M, Huggard P R, Cummings M, Ramm G A, Chenevix-Trench G
Primary Institution: The Queensland Institute of Medical Research
Hypothesis
CCL2 may play a role in the pathobiology of ovarian cancers.
Conclusion
CCL2 expression is silenced or downregulated in most ovarian cancer cell lines and primary adenocarcinomas.
Supporting Evidence
- CCL2 is expressed in normal human ovarian surface epithelium cells.
- Loss of heterozygosity at the CCL2 locus was found in 70% of primary tumors.
- CCL2 expression was detected in only a small percentage of epithelial cells in primary ovarian tumors.
Takeaway
This study found that a protein called CCL2, which helps the immune system, is often missing in ovarian cancer, which might help the cancer grow.
Methodology
The study involved analyzing CCL2 expression in ovarian cancer cell lines and primary tumors using techniques like RT-PCR and Northern blot analysis.
Limitations
The study did not detect mutations in the CCL2 coding sequence in the primary ovarian adenocarcinomas.
Participant Demographics
The study included 97 patients with various types of ovarian adenocarcinomas, including serous, endometrioid, mucinous, and clear-cell tumors.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website